Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

PRX-002 enters phase I for Parkinson's disease

April 11, 2014

World Parkinson's Day News: recent pathological insights and repurposing efforts

April 11, 2014

Alkermes reports topline results from a pivotal phase III study of aripiprazole lauroxil

April 10, 2014

Roche discloses novel TaR-1 ligands

April 10, 2014

TRV-130 begins phase II for acute postoperative pain after bunionectomy

April 9, 2014

AbbVie designs new 5-HT2C receptor agonists

April 9, 2014

Abbott and AbbVie disclose new PDE10A inhibitors

April 8, 2014

Aptiom launched in the U.S. for use as adjunctive treatment of partial-onset seizures

April 8, 2014

Mitsubishi Tanabe Pharma discloses new TRPM8 agonists for chronic pain

April 8, 2014

Preclinical efficacy of novel PDE10A inhibitors suggests potential for schizophrenia therapy

April 7, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...